Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling

Xiangyan Li1, Yi-Ting Chen1, Peizhen Hu1,2, and Wen-Chin Huang1

Abstract

Current research links aberrant lipogenesis and cholesterogenesis with prostate cancer development and progression. Sterol regulatory element-binding proteins (SREBP; SREBP-1 and SREBP-2) are key transcription factors controlling lipogenesis and cholesterogenesis via the regulation of genes related to fatty acid and cholesterol biosynthesis. Overexpression of SREBP has been reported to be significantly associated with aggressive pathologic features in human prostate cancer. Our previous results showed that SREBP-1 promoted prostate cancer growth and castration resistance through induction of lipogenesis and androgen receptor (AR) activity. In the present study, we evaluated the anti–prostate tumor activity of a novel SREBP inhibitor, fatostatin. We found that fatostatin suppressed cell proliferation and anchorage-independent colony formation in both androgen-responsive LNCaP and androgen-insensitive C4-2B prostate cancer cells. Fatostatin also reduced in vitro invasion and migration in both the cell lines. Further, fatostatin caused G2–M cell-cycle arrest and induced apoptosis by increasing caspase-3/7 activity and the cleavages of caspase-3 and PARP. The in vivo animal results demonstrated that fatostatin significantly inhibited subcutaneous C4-2B tumor growth and markedly decreased serum prostate-specific antigen (PSA) level compared with the control group. The in vitro and in vivo effects of fatostatin treatment were due to blockade of SREBP-regulated metabolic pathways and the AR signaling network. Our findings identify SREBP inhibition as a potential new therapeutic approach for the treatment of prostate cancer. Mol Cancer Ther; 13(4); 855–66. ©2014 AACR.

Introduction

Prostate cancer is the most prevalent malignancy diagnosed in males and the second leading cause of cancer-related mortality in the United States and Europe (1, 2). There is currently no effective therapy for advanced cancer progression. Epidemiologic evidence is mounting for a close relationship between dietary high fat intake and prostate carcinogenesis and lethal progression (3–5). Accumulated experimental research also suggests that there is a relationship between dietary fatty acid anabolisms, could potentially be a novel therapeutic approach for malignant prostate cancer. Mol Cancer Ther; 13(4); 855–66. ©2014 AACR.

Sterol regulatory element-binding proteins (SREBP) are basic helix–loop–helix leucine (bHLH) zipper transcription factors that transcriptionally activate genes involved in fatty acid and cholesterol biosynthesis and homeostasis (12, 13). Precursor SREBPs are synthesized as endoplasmic reticulum (ER) membrane-bound forms. Through sequentially proteolytic cleavage by site-1 (S1P) and site-2 (S2P) proteases, the N-terminus of SREBPs translocate into the nucleus and trigger the expression of target genes having sterol regulatory elements (SRE), cis-acting elements in their 5′-flanking promoter regions (13, 14). Three isoforms of SREBP have been identified, including SREBP-1a, SREBP-1c, and SREBP-2 (13, 15). SREBP-1a mainly regulates genes associated with fatty acid and cholesterol biosynthesis (12, 13). SREBP-2 is particularly involved in the transcriptional control of cholesterol anabolism (16). Overexpression of SREBP-1 has been found in human prostate cancer tissues and LNCaP xenograft tumor tissues during androgen refractory/castration-resistant progression (17, 18). In addition, our recent data showed that SREBP-1 and its nuclear form were highly elevated in clinical prostate cancer specimens with aggressive pathologic features compared with nontumor prostate tissues (18). Furthermore, SREBP-1 promoted cell viability and castration-resistant progression via alterations of lipogenesis, oxidative stress, and androgen receptor (AR) expression in prostate cancer cells (18). Previous reports revealed that SREBP-2

Authors’ Affiliations: 1Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California and 2Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China

Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

Corresponding Author: Wen-Chin Huang, Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048. Phone: 310–423–7378; Fax: 310–423–8543; E-mail: wen-chin.huang@csbs.org

doi: 10.1158/1535-7163.MCT-13-0797
©2014 American Association for Cancer Research.
activity was increased in prostate cancer cells and targeting this activity altered cell membrane cholesterol content and inhibited signaling transduction mediated by cholesterol-rich lipid rafts (11, 17, 19–21). These discoveries provide a rationale for blocking SREBPAs and their controlling metabolic and signaling pathways by pharmacologic intervention as a potential approach for prostate cancer therapy.

Fatostatin, a nonsterol diarylthiazole derivative, was originally developed from a chemical library to inhibit insulin-induced adipogenesis (22) and decreased the amounts of fatty acid, triglyceride and low-density lipoprotein and reduce body weight by perturbing the nuclear translocation of SREBP in obese mice with low cytotoxicity (23). Fatostatin has been shown to have the potential efficacy in glioma cells (24). Here, we report that fatostatin is a novel anti–prostate tumor agent that suppresses cell proliferation, tumorigenesis, and progression and induces apoptotic death in prostate cancer cells in vitro and in vivo by blocking SREBP activation and inhibiting fatty acid and cholesterol biosynthesis as well as AR signaling. This study indicates that inhibition of SREBP could be exploited as a promising therapy against malignant prostate cancer.

Materials and Methods

Cell lines and culture conditions

The human prostate cancer LNCaP cell line and C4-2, a LNCaP lineage-derived bone metastatic subline, were kindly provided by Dr. Leland W. K. Chung (Cedars-Sinai Medical Center, Los Angeles, CA) in December 2010 (25). Mouse embryo fibroblast NIH-3T3 cells were purchased from the American Type Culture Collection (ATCC) in November 2013. These cell lines have not been further authenticated. LNCaP and C4-2B cells were cultured in T-Medium (Life Technologies). NIH-3T3 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies). Mouse embryo fibroblast NIH-3T3 cells were purchased from Addgene.

Compounds and reagents

Fatostatin (4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-2-propylpyridine hydrobromide) was purchased from Chembridge Corporation and its chemical structure is described (11, 19, 20). Fatostatin has been shown to have the potential efficacy (23). Fatostatin has been shown to have the potential efficacy in glioma cells (24). Here, we report that fatostatin is a novel anti–prostate tumor agent that suppresses cell proliferation, tumorigenesis, and progression and induces apoptotic death in prostate cancer cells in vitro and in vivo by blocking SREBP activation and inhibiting fatty acid and cholesterol biosynthesis as well as AR signaling. This study indicates that inhibition of SREBP could be exploited as a promising therapy against malignant prostate cancer.

Quantitative reverse transcription (qRT)-PCR analysis

Total RNA from each sample was isolated by RNeasy mini Kit (Qiagen). First-strand cDNA was synthesized from total RNA (1 μg) using SuperScript III reverse transcriptase (Life Technologies) with random hexamer primers. Quantitative PCR (qPCR) was performed on ABI 7500 Fast Real-Time PCR System using the SYBR Green PCR Master mix from Applied Biosystems. The oligonucleotide primer sets, including ATP citrate lyase (ACl), fatty acid synthase (FASN), stearoyl-CoA desaturase-1 (SCD-1), 3-hydroxy-3-methyl-glutaryl-CoA synthase 1 (HMGCASI), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCAR), mevalonate kinase (MKV), mevalonate 5-pyrophosphate decarboxylase (MVD), low-density lipoprotein receptor (LDLR), insulin-induced gene 1 (INSIG1), SREBP cleavage activating protein (SCAP), and β-actin, are listed in Supplementary Table S1.

Western blot analysis

Cell lysates were prepared from prostate cancer cells as previously described (26) and Western blot analysis was performed using Mini-PROTEAN system (Bio-Rad). Primary antibodies against SREBP1 (sc-8984), FASN (sc-48357), HMGCAR (sc-38327), PSA (sc-7638) and β-actin (sc-7778; Santa Cruz Biotechnology), SREBP2 (ab72856 and ab112046; Abcam), AR (PG-21; Millipore), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 21185; Cell Signaling Technology) and horseradish peroxidase-conjugated secondary antibodies (GE Healthcare Bio-Sciences Corp) were used and membranes were visualized using a chemiluminescence reagent (Amersham Biosciences).
Filipin and Oil Red O stainings
For filipin staining, cells were fixed, quenched with glycine, and stained by filipin solution (50 μg/mL in PBS) for 1 hour. The filipin staining images were visualized by fluorescence microscopy. For Oil Red O staining, cells treated with vehicle or fatostatin were stained by Oil Red O working solution and were examined by a phase-contrast microscope (18).

Quantification of fatty acid and total cholesterol
The amounts of fatty acid and cholesterol were measured using the Free Fatty Acid Quantification Kit and the Cholesterol/Cholesterol Ester Detection Kit according to the manufacturer’s instructions (Abcam) in cells treated with vehicle or fatostatin (21).

Cell cycle and apoptosis analysis
Cells treated with vehicle or fatostatin for 48 hours were fixed, stained with PI (25 μg/mL), and analyzed by FACSscan flow cytometer on the basis of 2N and 4N DNA content. Apoptotic cell death was assessed in cells treated with vehicle or fatostatin using Annexin V-FITC/PI Apoptosis Detection Kit (BD Bioscience). For caspase activity assay, cells treated with vehicle or fatostatin for 48 hours were measured for caspase-3/7 enzymatic activities using Caspase-Glo 3/7 Assay Systems (Promega). After treatment with vehicle or fatostatin for 72 hours, anti-caspase-9 (9502), anti-caspase-3 (9665), and PARP (9542) primary antibodies (Cell Signaling Technology) were used for Western blot analysis.

Luciferase activity assay
NIH-3T3 cells were transfected with pHMGCoASyn-Luc, pFASN-700-Luc, pFASN-700-mutSRE-Luc, pLDLR-Luc, and pLDLR-mutSRE constructs using Lipofectamine LTX Reagent (Life Technologies), following which they were treated with vehicle or fatostatin for 20 hours. The luciferase activity was measured by the Luciferase Assay Kit (Promega) and normalized to β-galactosidase luciferase activity by cotransfection of β-galactosidase control vector. pSRE-Luc, SREBP-1 (Origene Technologies), SREBP-2, CMV500 A-SREBP1, and CMV500 A-SREBP2 (Addgene) vectors were transfected into cells as described above.

Mouse xenograft experiments
All animal experiments were performed in accordance with the protocol approved by the Cedars-Sinai Medical Center Institution Animal Care and Use Committee. Athymic nu/nu male mice (4-week-old; Taconic) were implanted subcutaneously with C4-2B cells (1 × 10⁶). Tumor burdens were monitored by calipers and calculated using the formula $V = \frac{1}{2} \times length \times width²$. Mice bearing C4-2B tumors with a mean volume of 100 mm³ were randomly divided into vehicle control (sterile PBS) or fatostatin (15 mg/kg) groups with intraperitoneal injection for 42 days (23). Blood specimens were collected and serum PSA was determined by AIA-360 Immunoassay Analyzer (Tosoh Bioscience). At the end of the animal experiments, tumor xenografts were harvested for further analysis.

Immunohistochemical staining
Immunohistochemical (IHC) staining was performed as described previously (27). The paraffin-embedded C4-2B tumor tissue slides were analyzed for Ki67 (1:200 dilution; Abcam), cleaved PARP (1:30 dilution), HMGR (1:50 dilution), FASN (1:100 dilution; Santa Cruz Biotechnology), AR (1:100 dilution; Millipore), and PSA (1:100 dilution; Vector Labs) expression. The percentages of Ki67-positive cells (proliferation) or cleaved PARP-positive cells (apoptosis) were calculated in five randomly selected microscopic fields at a ×200 magnification.

Statistical analysis
All quantitative results are expressed as means ± SD. Statistically significant differences were obtained using a two-tailed Student t test. A value of $P < 0.05$ was considered to be statistically significant in all experiments.

Results
Fatostatin inhibits cell proliferation, invasion, and migration of prostate cancer cells in vitro
To evaluate the effects of fatostatin on human prostate cancer cell lines with biologic heterogeneity, we carried out a set of cell survival assays by treating androgen-responsive LNCaP and androgen-independent C4-2B cells with fatostatin at serial dilutions, as described in Materials and Methods. The half maximal inhibitory concentrations (IC₅₀, 72 hour treatment) of fatostatin in LNCaP and C4-2B cells were 10.4 and 9.1 μM, respectively (Fig. 1A). In addition, we determined the growth rate of each cell line by counting the total number of cells with or without fatostatin treatment. The growths of LNCaP and C4-2B cells were significantly inhibited by fatostatin in a dose- and time-dependent manner (Fig. 1B). Next, we examined the effect of fatostatin on the anchorage-independent colony formation ability in prostate cancer cells. After 3-week incubation, fatostatin notably inhibited the number and size of colony formation in LNCaP and C4-2B cells in a dose-dependent manner (Fig. 1C).

One of the hallmarks of progressive and metastatic cancer cells is their ability to invade surrounding tissues and migrate efficiently. The effect of fatostatin on the invasion and migration potentials of LNCaP and C4-2B cells was determined. After a 48-hour treatment, fatostatin significantly decreased the invasive (Fig. 1D) and migratory (Fig. 1E) capabilities of LNCaP and C4-2B cells compared with the untreated group. Take together; these data indicate that fatostatin inhibits proliferation, anchorage-independent colony formation, invasion, and migration in both androgen-responsive and androgen-independent prostate cancer cells.
Fatostatin causes G2–M cell-cycle arrest and induces caspase-mediated apoptosis in prostate cancer cells

The effects of fatostatin on cell-cycle distribution and apoptosis in prostate cancer cells were determined. LNCaP and C4-2B cells were exposed to various concentrations of fatostatin for 48 hours. Subsequently, the percentage of cell-cycle distribution was measured by flow cytometry–based PI staining. As shown in Fig. 2A, fatostatin induced a significant accumulation in the G2–M phase in LNCaP and C4-2B cells. Next, the level of apoptosis induced by fatostatin was examined using simultaneous staining with FITC-coupled Annexin V and PI. The population of LNCaP and C4-2B cells in the early (bottom right) or late apoptotic (top right) stage was increased by fatostatin treatment (Fig. 2B). Only 1.84% or 0.57% of the late stage of apoptotic cells was detected in LNCaP or C4-2B without fatostatin treatment. However, the percentages of late apoptotic cells were significantly increased in both LNCaP (52.88%) and C4-2B (30.01%) cells after fatostatin (20 μmol/L) treatment.

To further define the mechanism underlying fatostatin-induced apoptotic cell death, we first examined a number of well-defined apoptotic markers involving caspase-3/7 enzymatic activity in prostate cancer cells by luminescence cleavage of specific substrates (Promega). A marked increase of caspase-3/7 enzymatic activities was found in LNCaP and C4-2B cells exposed to fatostatin with a dose-dependent manner (Fig. 2C). Next, we determined the expression patterns of caspases by Western blot analysis. Fatostatin decreased the expression of full-length caspases and increased the expression of cleaved caspase-9, caspase-3, and PARP, a downstream factor of caspases, in LNCaP and C4-2B cells (Fig. 2D). This indicates that fatostatin activates the apoptotic cascade pathway in prostate cancer cells. Collectively, these results suggest that fatostatin causes G2–M cell-cycle arrest and induces caspase-dependent programmed cell death in LNCaP and C4-2B cells.
Fatostatin inhibits SREBP processing and transcriptional activity, and key enzymes for lipogenesis and cholesterogenesis, to reduce fatty acid and cholesterol levels in prostate cancer cells

To reveal the molecular mechanism of fatostatin action in prostate cancer, we first investigated the nuclear translocation and transcriptional activity of SREBPs and their regulated anabolic pathways affected by fatostatin. As shown in Fig. 3A, expression of both nuclear SREBP-1 and SREBP-2 were decreased by fatostatin in a dose-dependent manner in LNCaP and C4-2B cells. In addition, immunofluorescence staining showed that fatostatin led to a reduction of SREBP-1 and SREBP-2 in the nuclear compartmentalization (Supplementary Fig. S2).

Next, we determined transcriptional expression of SREBP-controlled anabolic genes affected by fatostatin, including ACL, FASN, and SCD-1 for lipogenesis, HMGCS1, HMGCR, MVK, MVD, and LDLR for cholesterogenesis, two chaperones, INSIG1 and SCAP. As shown in Fig. 3B, fatostatin significantly downregulated mRNA expression of these genes in LNCaP and C4-2B cells. Fitting with the effects of fatostatin on SREBP target mRNA expression, FASN and HMGCR proteins were also suppressed by fatostatin in a dose-dependent pattern in prostate cancer cells (Fig. 3A).
To confirm that fatostatin acts on the SREBP pathways, the transcriptional ability of SREBP was determined by the promoter-luciferase (Luc) and mutant constructs assays for several SREBP-regulated genes. As shown in Fig. 3C, fatostatin significantly decreased the activities of the pHMGCoASyn-Luc, pFASN-700-Luc, and pLDLR-mutSRE reporters. The relative luciferase activity was normalized by the β-galactosidase activity and assigned as 100% in the absence of fatostatin. **P < 0.001 significant differences from the absence of fatostatin.**
Fatostatin exhibits antitumor efficacy in a subcutaneous C4-2B xenograft mouse model

In view of the potent in vitro effect of fatostatin against prostate cancer cells (Figs. 1 and 2), we next examined the efficacy of fatostatin on human prostate cancer growth in immunodeficient mice. The volumes of subcutaneous C4-2B tumors treated with fatostatin were significantly smaller than those in the vehicle-treated control group over 42 days of observation (Fig. 4A). Moreover, at the end of the animal experiment, the average weight of the excised tumors harvested from control and fatostatin-treated groups were examined by Western blot and IHC staining analysis. As shown in Fig. 4B and C, the expressions of HMGCR and FASN proteins in tumors harvested from control and fatostatin-treated groups were lower compared with vehicle-treated tumors. This suggests that fatostatin exerted its antitumor effects by decreasing the expression of SREBP target genes associated with biosynthesis of fatty acid and cholesterol in a xenograft mouse model, in accord with the observation that lipogenesis and cholesterol in prostate cancer cells.

Fatostatin decreases expression of AR and its target gene PSA in prostate cancer in vitro and in vivo

AR activity is essential for prostate cancer development, growth, and castration-resistant progression. We previously showed that SREBP-1 transcriptionally induced AR expression and activity in prostate cancer cells (18). Here, we tested the idea that blocking SREBP-1 transcriptional activity by fatostatin inhibits the AR signaling in AR-positive LNCaP and C4-2B cells. As we expected, fatostatin affected the expression of AR and its downstream target gene PSA via dose-dependent inhibition in LNCaP and C4-2B cells (Fig. 6A). We also observed that fatostatin blocked AR nuclear translocation in both cell lines (Supplementary Fig. S4). Furthermore, the results of Western blot analysis at different time points showed that fatostatin first inhibited the nuclear translocation of SREBP-1 and SREBP-2 (at 6 hours) and subsequently decreased AR expression (at 12 hours) in LNCaP and C4-2B cells (Fig. 6B). It indicates that SREBPs are main targets of fatostatin, but not AR. Consistent with the in vitro results, fatostatin inhibited the expression of both AR and PSA compared with the vehicle group as determined by Western blot (Fig. 6C) and IHC staining (Fig. 6D) in a C4-2B tumor xenograft mouse model. In addition, the serum PSA levels of the fatostatin-treated mice were significantly reduced compared with the vehicle control group (Fig. 4C). These in vitro and in vivo results suggest that this specific SREBP...
inhibitor inhibited AR expression and function in prostate cancer.

Discussion

Cancer cells reprogram the metabolic pathways to meet their abnormal demands for uncontrolled proliferation and survival. Accumulated research suggests that upregulation of de novo lipid synthesis is associated with prostate cancer malignancy (28, 29). The altered fatty acid and cholesterol biosynthesis in cancer cells regulated by oncogenic signaling pathways, tumor microenvironment, and metabolism-related transcription regulators are believed to be important for the initiation and progression of tumors (30, 31). Understanding the molecular mechanism for
reprogramming lipogenesis and cholesterogenesis is the key to developing a successful therapy for eliminating prostate cancer.

SREBP's are transcription factors that predominantly activate expression of genes related to biosynthesis of long-chain fatty acid, triglyceride, and cholesterol and cholesterol uptake by binding to the SRE located in the 5'-flanking promoter region of these genes in the nucleus (32–34). Nuclear SREBP-1 proteolytic activation is under the control of hormones or signal transduction systems.

Figure 5. Fatostatin inhibits the mRNA and protein levels of SREBP downstream genes in C4-2B xenograft tumors. A, fatostatin inhibited mRNA expression of SREBP downstream target genes, including ACL, FASN, SCD-1, HMGCS1, HMGCR, MVK, and MVD and two chaperones, INSIG-1 and SCAP, compared with the control group. Total RNA was extracted from C4-2B xenograft tumors in nude mice treated with vehicle or fatostatin (4 tumors for each group). * P < 0.05; ** P < 0.01; *** P < 0.001 significant differences from vehicle-treated control tumors. B, Western blot analysis showed that fatostatin decreased expression of FASN and HMGCR in C4-2B xenograft tumors compared with the vehicle group. GAPDH was used as a loading control. C, the results of IHC staining showed that the expression of FASN and HMGCR was decreased in the fatostatin-treated C4-2B xenograft tumors compared with the vehicle group. Scale bar, 100 μm.

Figure 6. Fatostatin decreases expression of AR and its target gene PSA in prostate cancer cells and in a xenograft mouse model. A, after a 24-hour treatment, fatostatin inhibited the expression of AR and PSA in LNCaP and C4-2B cells in a dose-dependent manner. B, fatostatin (10 μmol/L) blocked activation of SREBP-1 and SREBP-2 (at 6 hours) and subsequently inhibited AR and PSA protein expression (at 12 hours) in LNCaP and C4-2B cells. P, precursor form; N, nuclear form. C, fatostatin also suppressed the expression of AR and PSA in C4-2B xenograft tumors compared with the vehicle group; GAPDH was used as a loading control. D, IHC staining showed that the expression of AR and PSA was reduced by fatostatin in C4-2B xenograft tumors. Scale bar, 100 μm.
and SREBP-2 nuclear translocation is regulated by the ER cholesterol content, reflecting its deep involvement in cholesterol homeostasis (35). SREBPs have been shown to promote prostate cancer growth, development, and progression. Importantly, clinical evidence revealed that overexpression of SREBP-1 and its nuclear form is associated with prostate cancer development and lethal castration resistance (17, 18). These experimental and clinical results offer a rationale for targeting SREBP transcriptional activity and regulated downstream metabolic pathways as a potential therapeutic approach for prostate cancer.

Transcription factors may be difficult to directly target by small molecules. However, the cytoplasmic maturation and nuclear translocation of SREBPs provides a feasible targeting approach. In the present study, a new SREBP blocker, fatostatin, was tested for anti–prostate cancer efficacy in vitro and in vivo by perturbing SREBP maturation and nuclear translocation. Fatostatin significantly inhibited cell proliferation and induced G2–M cell-cycle arrest and caspase-dependent apoptosis in AR- and PSA-positive LNCaP and C4-2B prostate cancer cells. Fatostatin also suppressed subcutaneous C4-2B tumor growth and decreased serum PSA levels in a xenograft mouse model. Furthermore, through downregulation of SREBP-controlled metabolism-related enzymes, including FASN and HMGCR, fatostatin inhibited the levels of fatty acid and cholesterol in prostate cancer cells. Our data reveal an important and significant insight, that blocking the maturation and translocation of SREBPs provides a promising approach for perturbing the cancer metabolic program and attenuating prostate tumor growth.

Fatty acid is an essential constituent of all biologic membrane lipids and an important substrate for energy storage and metabolism. ACL, FASN, and SCD-1 are three primary enzymes at rate-limiting steps for biosynthesis of long-chain fatty acid. Markedly increased ACL expression and activity have been reported in cancer cells (36). FASN is highly expressed and associated with poor prognosis in human carcinomas including prostate cancer and has been considered as a metabolic oncogene (37–39). SCD-1 plays a critical role in the regulation of carcinogenesis, cancer cell proliferation, and programmed cell death (40). In this study, we demonstrated that fatostatin inhibited expression of ACL, FASN, and SCD-1 and the levels of intracellular fatty acid in prostate cancer cells and a xenograft tumor model. The inhibitory mechanism of fatostatin could be due to decreasing SREBP-1 transcriptional activity, as SREBP-1 has been demonstrated to transcriptionally mediate expression of these three lipogenic genes (12). The data suggest that fatostatin decreased the expression of cancer-associated lipogenic genes and further reduced intracellular fatty acid, to inhibit prostate cancer growth in vitro and in vivo.

Cholesterol is one of the major components of lipid rafts, specialized microdomains of the plasma membrane that serve as organizing centers for the assembly of signaling molecules (41). Therefore, rapidly proliferating cancer cells with highly activated signal transduction networks, such as prostate cancer cells, are likely to have an enhanced requirement for cholesterol (42). Besides, cholesterol is a metabolic precursor for biosynthesis of steroid hormones, including androgens. SREBP-2 is a master transcription regulator that upregulates several...
inhibit the expression of these cholesterogenic genes, such as HMGCS1, HMGCR, and LDLR. HMGCR activity was increased in ex vivo LNCaP tumors during progression to a castration-resistant state in xenograft mouse models (43, 44). Expression of LDLR has been demonstrated to be elevated in prostate cancer cells compared with normal cells, which could be due to the lack of sterol feedback regulation controlled by SREBP-2 in prostate cancer cells (45). Blocking the intracellular cholesterol supply through inhibition of the LDLR pathway induced tumor cell death in vivo (46). Our results showed that inhibition of SREBP-2 activity by fatostatin suppressed the expression of these cholesterogenic genes and significantly reduced the levels of intracellular cholesterol in prostate cancer in vitro and in vivo, which is an essential component and precursor for the lipid raft-mediated survival signaling pathways and intracrine androgen biosynthesis. These results suggest that interrupting the SREBP-2-regulated cholesterogenic pathway may offer an attractive anti–prostate cancer approach.

Androgens exert their effects by interacting with AR to release HSPs and allowing nuclear localization and DNA interaction. AR, a critical transcription, growth, and survival factor, plays a key role in regulation of androgen-responsive organs during normal development and maintenance as well as prostate cancer growth and lethal hormone refractory/castration-resistant progression (47, 48). The AR signaling axis provides a promising targeted therapy for prostate cancer malignancy. Different strategies have been successfully attempted to target AR directly through gene transcription or translation or blocking the interaction between AR and its cofactors and their downstream functions in prostate cancer cells (26, 49). We previously reported that SREBP-1 mediated AR transcriptional expression and activity by a mechanism of binding the AR promoter region in prostate cancer cells (18). In addition, knocking down SREBP-1 led to decreases in AR mRNA and protein expression and inhibited prostate cancer cell viability (18, 27). Furthermore, unpublished results showed that silencing SREBP-2 by specific short hairpin RNA (shRNA) decreased expression of AR and its downstream target gene PSA in prostate cancer cells. These findings suggest that SREBPs could have an essential role as an important regulator for AR signaling. In this study, we demonstrated that interrupting SREBP activity by fatostatin suppressed the expression of AR and PSA in both androgen-responsive LNCaP and androgen-independent C4-2B cells. In a C4-2B xenograft mouse model, fatostatin also inhibited AR and PSA expression and decreased serum PSA levels. Taken together, the in vitro and in vivo results revealed an important mechanism by which fatostatin inhibited AR expression and activity via blockade and inhibition of the nuclear translocation and transcriptional activity of SREBP in prostate cancer cells. This could be exploited as a novel and improved therapeutic application by cotargeting the dysregulated metabolic pathways and the AR signaling axis using a SREBP inhibitor, such as fatostatin, to treat prostate cancer and hormone refractory/castration-resistant progression.

In summary, we uncovered the underlying molecular mechanisms by which fatostatin suppresses prostate cancer growth and tumorigenicity (Fig. 7). Fatostatin was shown to inhibit cell proliferation, anchorage-independent colony formation and progression, and induce the apoptotic pathway through interruption of SREBP nuclear translocation and transcriptional inhibition of SREBP-regulated metabolic gene expression and AR activity in both androgen-responsive and androgen-independent prostate cancer cells. These biologic effects of fatostatin provide a novel strategy for prostate cancer therapy. Future studies will determine the efficacy of fatostatin in advanced prostate cancer as well as various cancer types.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: X. Li, W.-C. Huang
Development of methodology: X. Li, Y.-T. Chen, P. Hu, W.-C. Huang
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): X. Li, Y.-T. Chen, P. Hu
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): X. Li, Y.-T. Chen, P. Hu, W.-C. Huang
Writing, review, and/or revision of the manuscript: X. Li, W.-C. Huang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): X. Li, W.-C. Huang
Study supervision: W.-C. Huang

Acknowledgments
The authors thank Dr. Leland Chung and their colleagues at Cedars-Sinai Medical Center for helpful discussions and comments, and Gary Mawyer for editing the article. The authors also thank Dr. Timothy F. Osborne at Sanford-Burnham Medical Research Institute and Dr. Hitoshi Shimano at Tsukuba University for providing the promoter reporter constructs.

Grant Support
This work was supported by a grant from the Department of Defense (W81XWH-08-1-0321), the Cedars-Sinai Garber Awards for Cancer Science and NIH/National Center for Advancing Translational Sciences (NCATS, Grant # UL1TR000124; to W.-C. Huang).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 23, 2013; revised December 18, 2013; accepted January 20, 2014; published OnlineFirst February 3, 2014.

References


Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling

Xiangyan Li, Yi-Ting Chen, Peizhen Hu, et al.